Trade PURETECH HEALTH PLC ORD 1P - PRTC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0090 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023256% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001338% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | GBP | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.4365 |
| Open | 1.4365 |
| 1-Year Change | -35.6% |
| Day's Range | 1.4045 - 1.4685 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 1.4365 | 0.0020 | 0.14% | 1.4345 | 1.4525 | 1.3785 |
| Mar 28, 2025 | 1.4605 | 0.1320 | 9.94% | 1.3285 | 1.4645 | 1.3185 |
| Mar 27, 2025 | 1.3385 | 0.0860 | 6.87% | 1.2525 | 1.3545 | 1.2225 |
| Mar 26, 2025 | 1.2665 | -0.0020 | -0.16% | 1.2685 | 1.2745 | 1.2565 |
| Mar 25, 2025 | 1.2785 | -0.0300 | -2.29% | 1.3085 | 1.3085 | 1.2765 |
| Mar 24, 2025 | 1.3085 | 0.0200 | 1.55% | 1.2885 | 1.3105 | 1.2785 |
| Mar 21, 2025 | 1.2585 | -0.0500 | -3.82% | 1.3085 | 1.3085 | 1.2585 |
| Mar 20, 2025 | 1.3145 | -0.0040 | -0.30% | 1.3185 | 1.3385 | 1.2945 |
| Mar 19, 2025 | 1.3185 | 0.0100 | 0.76% | 1.3085 | 1.3345 | 1.3085 |
| Mar 18, 2025 | 1.3105 | 0.0180 | 1.39% | 1.2925 | 1.3405 | 1.2925 |
| Mar 17, 2025 | 1.2925 | -0.0180 | -1.37% | 1.3105 | 1.3105 | 1.2705 |
| Mar 14, 2025 | 1.3045 | 0.0560 | 4.49% | 1.2485 | 1.3065 | 1.2485 |
| Mar 13, 2025 | 1.2625 | -0.0040 | -0.32% | 1.2665 | 1.2805 | 1.2545 |
| Mar 12, 2025 | 1.2545 | 0.0000 | 0.00% | 1.2545 | 1.2585 | 1.2245 |
| Mar 11, 2025 | 1.2545 | -0.0520 | -3.98% | 1.3065 | 1.3065 | 1.2465 |
| Mar 10, 2025 | 1.3065 | -0.0140 | -1.06% | 1.3205 | 1.3305 | 1.2725 |
| Mar 7, 2025 | 1.3465 | 0.0160 | 1.20% | 1.3305 | 1.3625 | 1.3105 |
| Mar 6, 2025 | 1.3445 | -0.0580 | -4.14% | 1.4025 | 1.4045 | 1.3105 |
| Mar 5, 2025 | 1.4025 | 0.0040 | 0.29% | 1.3985 | 1.4085 | 1.3525 |
| Mar 4, 2025 | 1.3565 | -0.0440 | -3.14% | 1.4005 | 1.4045 | 1.3565 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Puretech Health plc Company profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders; microbiome-derived immune modulators for maternal and paediatric health; novel approach to oral delivery of biologics, vaccines, and other drugs; platform to address androgenetic alopecia; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist programme for the treatment of psychosis and cognition, including schizophrenia and Alzheimer''s; monoclonal antibody-based therapeutic to treat pancreatic cancer and other solid tumors; voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, such as depression, Alzheimer''s disease, multiple sclerosis, and Parkinson''s disease; platform and products that seek to explore and leverage the health potential of music; therapies for immune-mediated and infectious diseases based on rationally-defined consortium of human microbiome-derived bacteria; and novel antibody and cell therapies for treating cancer. It is also developing a milk exosome-based technology designed to enable the oral administration of biologics, nucleic acids, and complex small molecules; and a lipid prodrug technology to enable lymphatic targeting. In addition, the company''s medical device programme is developing a non-invasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder. PureTech Health plc was incorporated in 2015 and is headquartered in Boston, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
6 Tide Street
Suite 400
BOSTON
MASSACHUSETTS 02210
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com